ECM REMODELING IN EXCESSIVE FIBROPLASIA
过度纤维增生的 ECM 重塑
基本信息
- 批准号:2703826
- 负责人:
- 金额:$ 20.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-07-01 至 2002-06-30
- 项目状态:已结题
- 来源:
- 关键词:antisense nucleic acid blocking antibody cellular pathology collagen collagenase enzyme linked immunosorbent assay extracellular matrix fibrin fibrinolysis fibroblasts fibrosis gene expression genetic transduction growth factor receptors human tissue northern blottings plasminogen activator plasminogen activator inhibitors polymerase chain reaction scars tissue /cell culture tissue inhibitor of metalloproteinases transforming growth factors urokinase wound healing
项目摘要
To elucidate the cellular and molecular basis of excess scar formation
during wound repair. The present application will focus on the cellular
and molecular differences between normal scar and keloid fibroblasts
with a special emphasis on the altered regulation of the PAI/uPA system
in keloid fibroblasts. Information obtained from this study may lead to
development of methods for prevention and treatment of excess scar
formation during wound repair. The investigators will approach the long
term goal by elucidating the pathologic mechanisms of excess scar
formation using an in vitro fibroplasia model as an environment for
perturbing matrix remodeling directed by normal scar and fibrotic
fibroblasts. The investigators have demonstrated that keloid
fibroblasts exhibit changes in fibrin matrix remodeling by expressing
elevated levels of plasminogen activator inhibitor-1 (PAI-1) and basal
and transforming growth factor-beta (TGF-b) stimulated-levels of
collagen. These changes may be mediated at the TGF-b receptor level,
since a difference in the TGF-b type I receptor profile in keloid
fibroblasts was identified. The investigators hypothesize a) that
increased expression of PAI-1 in keloid fibroblasts leads directly to
defective fibrin degradation and persistent fibroplasia in keloids, and
b) that increased responsiveness to TGF-b, mediated by an altered
profile of receptors, induces this elevated PAI-1 expression in keloid
cells. The investigators will test these hypotheses with four specific
aims: Specific Aim 1: To characterize a matrix remodeling phenotype
for normal scar and keloid fibroblasts. Specific Aim II. To test for
the presence of a cause and effect relationship between uPA/PAI-1 and
acute changes in fibrin degradation by manipulating uPA/PAI phenotypic
expression in normal scar and keloid fibroblasts using retroviral
transduction of PAI-1/antisense PAI-1 into these cells. Specific Aim
III. To determine if a direct cause and effect relationship exists
between a specifically altered uPA/PAI-1 phenotype and the nature of the
remodeled ECM that develops over time. Specific Aim IV. To characterize
TGF-b receptors from keloid fibroblasts and determine whether ligand
binding or receptor signaling are responsible for the increased
synthesis of PAI-1 and collagen by keloid fibroblasts in this model.
阐明过度瘢痕形成的细胞和分子基础
在伤口修复过程中。 本申请将集中于蜂窝通信系统。
正常瘢痕和瘢痕疙瘩成纤维细胞之间的分子差异
特别强调派/uPA系统调节的改变
瘢痕疙瘩成纤维细胞中。从本研究中获得的信息可能导致
预防和治疗过度瘢痕的方法进展
在伤口修复过程中形成。 调查人员将接近长
通过阐明过度瘢痕的病理机制,
使用体外纤维增生模型作为环境,
干扰由正常瘢痕和纤维化引导的基质重塑
成纤维细胞 研究人员已经证明了瘢痕疙瘩
成纤维细胞表现出纤维蛋白基质重塑的变化,
纤溶酶原激活物抑制剂-1(派-1)和基础水平升高
和转化生长因子-β(TGF-β)刺激水平的
胶原 这些变化可能在TGF-β受体水平介导,
由于瘢痕疙瘩中TGF-β I型受体分布的差异
鉴定成纤维细胞。 研究人员假设a),
瘢痕疙瘩成纤维细胞中派-1表达增加直接导致
瘢痕疙瘩中的纤维蛋白降解缺陷和持续性纤维增生,以及
B)增加对TGF-B的反应性,由改变的
受体的表达,诱导瘢痕疙瘩中派-1表达升高
细胞 研究人员将用四个具体的假设来检验这些假设。
目的:具体目的1:表征基质重塑表型
正常瘢痕和瘢痕疙瘩成纤维细胞。具体目标二。 以测试
uPA/派-1与
通过操纵uPA/派表型的纤维蛋白降解的急性变化
使用逆转录病毒在正常瘢痕和瘢痕疙瘩成纤维细胞中的表达
将派-1/反义派-1转导到这些细胞中。 具体目标
三. 以确定是否存在直接因果关系
特异性改变的uPA/派-1表型与
随着时间的推移而发展的重塑ECM。 具体目标四。表征
瘢痕疙瘩成纤维细胞的TGF-β受体,并确定是否配体
结合或受体信号传导负责增加
该模型中瘢痕疙瘩成纤维细胞合成派-1和胶原。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAI-LAN TUAN其他文献
TAI-LAN TUAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAI-LAN TUAN', 18)}}的其他基金
FIBRIN GEL CONTRACTION & MATRIX SYNTHESIS BY FIBROBLASTS
纤维蛋白凝胶收缩
- 批准号:
2080031 - 财政年份:1991
- 资助金额:
$ 20.57万 - 项目类别:
FIBRIN GEL CONTRACTION & MATRIX SYNTHESIS BY FIBROBLASTS
纤维蛋白凝胶收缩
- 批准号:
3457405 - 财政年份:1991
- 资助金额:
$ 20.57万 - 项目类别:
相似海外基金
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
- 批准号:
10279706 - 财政年份:2021
- 资助金额:
$ 20.57万 - 项目类别:
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
治疗阿尔茨海默病的人源化单克隆 FSH 阻断抗体
- 批准号:
10693288 - 财政年份:2021
- 资助金额:
$ 20.57万 - 项目类别:
Study of suppressing effect by PAD4 catalytic cleft blocking antibody to rheumatoid arthritis and interstitial pneumonitis
PAD4催化裂隙阻断抗体对类风湿性关节炎和间质性肺炎抑制作用的研究
- 批准号:
17K09982 - 财政年份:2017
- 资助金额:
$ 20.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Characterization of a GPCR-blocking antibody for the treatment of breast cancer.
用于治疗乳腺癌的 GPCR 阻断抗体的表征。
- 批准号:
8199615 - 财政年份:2011
- 资助金额:
$ 20.57万 - 项目类别:
Regulation of the IL-31 function by the blocking antibody to IL-31 receptor
IL-31 受体阻断抗体对 IL-31 功能的调节
- 批准号:
22591230 - 财政年份:2010
- 资助金额:
$ 20.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The detection of blocking antibody against plasma thrombopoietin in subjects with childhood idiopathic thrombocytopenic purpura
儿童特发性血小板减少性紫癜患者血浆血小板生成素阻断抗体的检测
- 批准号:
13670842 - 财政年份:2001
- 资助金额:
$ 20.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)